Company record · updated August 5, 2026
Amylyx Pharmaceuticals, Inc.: 4 valuation observations from SEC filings
Every row below names the filing it came from. Coverage for this company runs December 16, 2021 to December 16, 2021.
4observations
1source filings
4verified rows
2021-12-16most recent as-of date
Source rails for this company: S-1 charter round (4).
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2021-12-16 | Series C-2 price per share | 8.7259 USD | — | VERIFIED | "Original Issue Price" defined for Series C-2 | 000119312521359405 |
| 2021-12-16 | Series C-1 price per share | 10.2658 USD | — | VERIFIED | "Original Issue Price" defined for Series C-1 | 000119312521359405 |
| 2021-12-16 | Series B price per share | 16.9741 USD | — | VERIFIED | "Original Issue Price" defined for Series B | 000119312521359405 |
| 2021-12-16 | Series A price per share | 1.2291 USD | — | VERIFIED | "Original Issue Price" defined for Series A | 000119312521359405 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price. The capabilities page states the full limits.